SLC5A2 and hepatocellular carcinoma: According to the literature, at a higher dose, CANA may affect not only SGLT2, but also other SGLT and glucose transporters15,16, particularly glucose transporter 1 (GLUT1), a frequently overexpressed glucose transporter in HCC.